Clearmind Medicine Inc. Q2 2026 Financial Results and Corporate Update

Clearmind Medicine Inc. (Nasdaq: CMND) reported its unaudited condensed interim consolidated financial results for the three and six months ended April 30, 2026. For the six months ended April 30, 2026, the company reported a net loss of $5,902,236, compared to a net loss of $1,855,549 for the same period in 2025. Operating expenses increased to $5,231,124 from $2,803,155 year-over-year, driven by higher general and administrative and R&D costs. As of April 30, 2026, the company held cash and cash equivalents of $11,415,719, up from $3,923,058 at the end of fiscal 2025, largely due to $11,995,163 provided by financing activities, including registered direct offerings and convertible loans. The company highlighted a 'going concern' risk due to accumulated deficits and negative cash flows. During the period, Clearmind effected two reverse splits (1-for-40 and 1-for-10) and converted significant promissory notes into common shares. The company continues its Phase I/IIa clinical trials for novel psychedelic medicines, primarily based in Israel.